Our story began in Bulgaria in 1997, when Dr. Milen Vrabevski founded Comac Medical as a family-owned company with a clear purpose: to advance clinical research through scientific expertise, personal commitment, and responsible delivery.
From a small team, the company built its reputation one study and one trusted relationship at a time. Those entrepreneurial roots shaped a culture of ownership and dedication that continues to guide us today.
From Local Roots to International Reach
Over nearly three decades, Comac Medical grew into one of Central and Eastern Europe’s leading full-service clinical research organizations, developing capabilities across the entire clinical development journey.
Its presence expanded to more than 20 countries, supported by an established Early Phase Clinical Research Unit and growing expertise across multiple therapeutic areas.
What began as a local organization became an international partner to biotech and pharmaceutical companies bringing new therapies closer to patients.
A New Chapter of Growth
In 2023, Comac Medical entered a new phase of growth following an investment from EdgeCap Partners, building on its strong foundations and extending its ambition across Europe.
In 2025, a new international leadership team was established, led by CEO Dr. Chris Smyth and supported by experienced industry leaders across operations, commercial strategy, and governance.
The company also strengthened its presence in key markets, establishing local operations in Germany, the United Kingdom, and the United States while continuing to build on its established position across Central and Eastern Europe.
ILIFE Consulting Joins the Group
In May 2025, ILIFE Consulting became part of the Group, adding recognized expertise in oncology, rare diseases, and complex early-phase biotech trials. Together, Comac Medical and ILIFE brought complementary strengths in strategic consulting, early-phase research, and integrated clinical trial delivery.
Becoming Clarenta
On 9 September 2026, we entered a new chapter with the launch of Clarenta—a unified clinical development company created to help sponsors navigate complexity with greater clarity, confidence, and control.
Inspired by the idea of clarity, the name Clarenta reflects both who we have become and the kind of partner we aim to be: clear in our guidance, open in our communication, and purposeful in moving clinical programmes forward. Although our identity is new, it is built on nearly three decades of experience, trusted relationships, and a shared commitment to clients and patients.
The Meaning Behind Our Name
Clarenta is inspired by clarus, the Latin word for clear or bright, and the idea of forward movement. It expresses our promise to create clarity where clinical development is complex—helping clients see further, make informed decisions, and move forward with confidence.
